Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019

BACKGROUND: Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part 1 of a 2-part randomized, placebo-controlled, double-blind study for patients with mild-to-moderate coronavirus disease 2019 (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Streinu-Cercel, Anca, Săndulescu, Oana, Preotescu, Liliana-Lucia, Kim, Jin Yong, Kim, Yeon-Sook, Cheon, Shinhye, Jang, Young Rock, Lee, Sang Joon, Kim, Sung Hyun, Chang, Ilsung, Suh, Jee Hye, Lee, Seul Gi, Kim, Mi Rim, Chung, Da Rae, Kim, Han Na, Streinu-Cercel, Adrian, Eom, Joong Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903348/
https://www.ncbi.nlm.nih.gov/pubmed/35295819
http://dx.doi.org/10.1093/ofid/ofac053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903348/
https://www.ncbi.nlm.nih.gov/pubmed/35295819
http://dx.doi.org/10.1093/ofid/ofac053

Ejemplares similares